Summary & Overview
HCPCS J9218: Leuprolide Acetate, per 1 mg
HCPCS Level II code J9218 denotes leuprolide acetate billed per 1 mg unit, an injectable GnRH agonist widely used in oncology, gynecology, and endocrinology. Nationally, accurate coding for J9218 matters because it drives drug reimbursement, impacts clinical cost management in outpatient infusion and ambulatory settings, and informs utilization monitoring for high-cost specialty pharmaceuticals. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9218 represents clinically and operationally, payer coverage considerations, common modifiers associated with injectable drug billing (listed separately), and the contexts in which J9218 is typically billed. The publication also outlines benchmark topics and policy considerations relevant to specialty injectable drugs, including unit-based billing implications and site-of-service distinctions. Data gaps in the input are noted where specific payer policies, ICD-10 pairings, and taxonomy mappings are not provided. This summary is intended to inform billing managers, revenue cycle professionals, and clinical leaders about the billing identity and typical use cases for HCPCS Level II code J9218.
Billing Code Overview
HCPCS Level II code J9218 represents leuprolide acetate, per 1 mg. This medication is a gonadotropin-releasing hormone (GnRH) agonist used clinically to suppress ovarian and testicular hormone production for conditions such as prostate cancer, endometriosis, uterine fibroids, and certain pediatric endocrinology indications.
-
Service type: Injectable pharmaceutical administration (drug supply)
-
Typical site of service: Outpatient infusion clinic or ambulatory care setting where injectable drugs are administered; may also be billed in hospital outpatient departments when the drug is furnished there.
Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, or related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9218 (leuprolide acetate, per 1 mg) is an adult or pediatric patient undergoing medical therapy that suppresses gonadotropin production. Common indications include prostate cancer, endometriosis, uterine fibroids prior to surgery, central precocious puberty, and chemical castration for metastatic hormone-sensitive conditions. A realistic scenario: a 68-year-old male with newly diagnosed metastatic prostate adenocarcinoma presents to an outpatient oncology clinic for initiation of androgen deprivation therapy. The clinician orders intramuscular depot leuprolide acetate; pharmacy dispenses the appropriate milligram dose based on the selected depot formulation and documents the billed unit as 1 mg per J9218. The typical clinical workflow: patient evaluation and informed consent by the oncology or urology provider → ordering and verification by clinic nurse or provider → medication preparation by pharmacy or clinic staff → administration in an outpatient infusion or procedure room (or office exam room for intramuscular/subcutaneous depot injections) → post-administration observation and documentation of lot number, dose, units billed, and any immediate adverse reactions. Typical site of service: outpatient oncology clinic, hospital outpatient department, urology clinic, or ambulatory infusion center. The nurse documents the administration using J9218 units corresponding to the milligrams administered and appends appropriate modifiers when required for payer reporting or circumstances of service.
Coding Specifications
| Modifier | Description | When to Use |
|---|